NCT07226726招募中1 期
Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome
The Foundation for Orthopaedics and Regenerative Medicine2 个研究点 分布在 2 个国家目标入组 20 人开始时间: 2025年1月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Oxygen Saturation
研究概览
简要总结
Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
详细描述
Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
- •Patients must be able to provide informed consent, or have a guardian who does.
- •Patient must be able to travel to the site of treatment.
排除标准
- •Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.
研究组 & 干预措施
Treatment Group
Experimental
干预措施: AlloEx exosomes (Biological)
结局指标
主要结局
Oxygen Saturation
时间窗: From enrollment to 6 months after treatment
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.EUCTR2012-002553-38-ESItziar Astigarraga Aguirre
招募中
2 期
Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft FunctionPoor Graft FunctionLow Donor T-cell ChimerismGraft-versus-host DiseaseNCT00603330University of Liege100
进行中（未招募）
不适用
Mesenchymal Stromal Cells (MSC) for the treatment of severe (grade II-IV) steroid-resistant Graft Versus Host Disease (GVHD): a phase I trial - MSC-GvHDGraft versus Host disease GvHD steroid resistantEUCTR2008-007869-23-ITAZIENDA OSPEDALIERA SAN GERARDO DI MONZA
暂停
1 期
Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple SclerosisMultiple SclerosisNCT07146087Biocells Medical20
Unknown
早期 1 期
Mesenchymal Stem Cell for Osteonecrosis of the Femoral HeadOsteochondritis of the Femoral HeadNCT00813267Jianming Tan15